Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
20.24
Dollar change
+0.84
Percentage change
4.33
%
Index- P/E- EPS (ttm)-2.27 Insider Own29.42% Shs Outstand15.06M Perf Week12.76%
Market Cap304.81M Forward P/E- EPS next Y-5.68 Insider Trans15.12% Shs Float10.63M Perf Month87.41%
Income-61.09M PEG- EPS next Q-1.61 Inst Own36.67% Short Float2.60% Perf Quarter215.76%
Sales0.00M P/S- EPS this Y40.18% Inst Trans5.05% Short Ratio2.22 Perf Half Y45.61%
Book/sh8.49 P/B2.38 EPS next Y7.86% ROA-72.08% Short Interest0.28M Perf Year13.07%
Cash/sh6.90 P/C2.93 EPS next 5Y- ROE-86.23% 52W Range4.00 - 21.90 Perf YTD156.53%
Dividend Est.- P/FCF- EPS past 5Y- ROI-63.51% 52W High-7.58% Beta2.13
Dividend TTM- Quick Ratio8.84 Sales past 5Y0.00% Gross Margin- 52W Low406.00% ATR (14)1.36
Dividend Ex-Date- Current Ratio8.84 EPS Y/Y TTM8.90% Oper. Margin0.00% RSI (14)80.12 Volatility6.78% 9.17%
Employees35 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.25 Target Price67.50
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q-392.91% Payout- Rel Volume1.25 Prev Close19.40
Sales Surprise- EPS Surprise-3.09% Sales Q/Q- EarningsNov 09 BMO Avg Volume124.62K Price20.24
SMA2030.99% SMA5092.29% SMA20082.07% Trades Volume155,374 Change4.33%
Date Action Analyst Rating Change Price Target Change
Aug-11-23Initiated CapitalOne Overweight $7
Feb-28-22Initiated Cantor Fitzgerald Overweight $10
Nov-08-21Initiated Credit Suisse Outperform $15
Oct-21-21Initiated William Blair Outperform
Oct-20-21Initiated BMO Capital Markets Outperform $19
Oct-13-21Initiated Oppenheimer Outperform $21
Today 08:00AM
Feb-19-24 08:50AM
Feb-07-24 08:00AM
Feb-06-24 08:59AM
Feb-05-24 08:00AM
08:00AM Loading…
Feb-02-24 08:00AM
Jan-24-24 12:14PM
Jan-05-24 08:30AM
Jan-02-24 08:00AM
Dec-18-23 04:30PM
Dec-10-23 11:00AM
Nov-30-23 08:00AM
Nov-09-23 09:48AM
08:00AM
Nov-08-23 04:30PM
09:00AM Loading…
Nov-02-23 09:00AM
Nov-01-23 08:00AM
Oct-09-23 08:30AM
08:00AM
Sep-25-23 08:00AM
Sep-21-23 08:00AM
Sep-15-23 08:00AM
Aug-11-23 04:05PM
Aug-04-23 04:51PM
Aug-02-23 08:00AM
Jun-22-23 08:00AM
Jun-20-23 08:00AM
Jun-13-23 08:00AM
May-12-23 04:05PM
May-10-23 08:00AM
08:00AM Loading…
Apr-13-23 08:00AM
Apr-10-23 04:05PM
Mar-31-23 08:00AM
Mar-23-23 08:00AM
Mar-09-23 08:00AM
Mar-08-23 04:05PM
Feb-17-23 08:20AM
08:10AM
08:00AM
Feb-16-23 04:05PM
Feb-03-23 04:05PM
Jan-30-23 08:00AM
Jan-27-23 01:10PM
Jan-25-23 08:00AM
Jan-24-23 04:25PM
Jan-13-23 08:00AM
Jan-10-23 08:00AM
Jan-04-23 08:00AM
Jan-03-23 08:00AM
Nov-10-22 04:05PM
Sep-26-22 08:00AM
Sep-23-22 08:00AM
Sep-15-22 08:00AM
Aug-12-22 04:05PM
Jun-23-22 04:05PM
Jun-20-22 10:59AM
Jun-07-22 08:00AM
Jun-06-22 08:00AM
May-27-22 08:00AM
May-17-22 08:00AM
May-12-22 04:05PM
Apr-28-22 08:00AM
Apr-26-22 04:05PM
Apr-22-22 08:00AM
Mar-31-22 08:00AM
Mar-25-22 07:30PM
Mar-21-22 08:30AM
Mar-18-22 04:05PM
Mar-10-22 08:00AM
Feb-28-22 08:00AM
Feb-24-22 05:19PM
Feb-02-22 01:38PM
Dec-08-21 11:15AM
08:30AM
Nov-20-21 08:21AM
Nov-12-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-15-21 09:39PM
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Velan Capital Investment Manag10% OwnerFeb 08Buy12.95350,0004,532,5001,188,500Feb 09 08:40 PM
Carlyle Group Inc.Former 10% OwnerFeb 08Buy12.95190,0002,460,5001,066,189Feb 12 06:23 PM
WIGGANS THOMAS GDirectorNov 28Buy0.6510,0006,48650,000Nov 30 04:05 PM
WIGGANS THOMAS GDirectorNov 21Buy0.6410,0006,38340,000Nov 22 04:06 PM
WIGGANS THOMAS GDirectorNov 20Buy0.6310,0006,30930,000Nov 20 08:14 PM
WIGGANS THOMAS GDirectorNov 17Buy0.6010,0005,96620,000Nov 20 08:14 PM
WIGGANS THOMAS GDirectorNov 16Buy0.6010,0005,96510,000Nov 20 08:14 PM
Lis WilliamDirectorOct 13Sale0.857,9656,77753,521Oct 13 06:56 PM
Mahal Jeetinder SinghSee RemarksJun 13Option Exercise0.719,0006,390296,223Jun 13 08:54 PM
Mahal Jeetinder SinghSee RemarksJun 13Sale1.669,00014,915287,223Jun 13 08:54 PM
French Anna LouiseDirectorApr 14Sale1.487,00010,36023,750Apr 14 04:19 PM
EMSTER KURT VONDirectorApr 13Sale1.499,07513,52421,175Apr 14 04:19 PM
Lis WilliamDirectorApr 13Sale1.448,50012,24061,486Apr 14 04:14 PM